Author Index Volume 21 (2009)

The issue number is given in front of the page numbers.

Aggarwal, R., see Brodie, A. (4) 201–215
Alván, G., see Barnes, H.J. (1,2) 13–22
Bailey, M., see Brodie, A. (4) 201–215
Barnes, H.J., G. Ragnarsson and G. Alván, Quality and safety considerations for recombinant biological medicines: A regulatory perspective (1,2) 13–22
Brodie, A., J. Kinross, M. Bailey, R. Aggarwal and C. Vincent, Using Failure Mode and Effects Analysis to identify hazards within resuscitation (4) 201–215
Bukharie, H.A., Can we prevent fatalities due to antituberculous drugs? (3) 153–160
Buttigieg, G.G., see Savona-Ventura, C. (3) 147–152
Buttigieg, G.G., see Savona-Ventura, C. (4) 177–184
Chandwani, H., see Gogtay, N.J. (1,2) 23–30
Chen, Y., Z.A. Wu, C. Zhang and Z. Wu, Overview of safety monitoring of biologicals in China (1,2) 69–74
Chopra, D., see Rehan, H.S. (4) 229–234
D’Arcy, E. and R. Moynihan, Can the relationship between doctors and drug companies ever be a healthy one? (4) 185–191
Dhingra, M.S., see Gogtay, N.J. (1,2) 23–30
Dukes, M.N.G., Tainted blood in Canada: An extraordinary history (1,2) 89–92
Felice, N., see Savona-Ventura, C. (4) 177–184
Fukushima, M., see Nishimura, T. (3) 161–167
Gatt, M., see Savona-Ventura, C. (3) 147–152
Gatt, M., see Savona-Ventura, C. (4) 177–184
Giezen, T.J., S.M.J.M. Straus and A.K. Mantel-Teeuwisse, Pharmacovigilance of biosimilars from a regulatory point of view: Is there a need for a specific approach? (1,2) 53–58
Gogtay, N.J., M.S. Dhingra, A. Yadav and H. Chandwani, Vaccine policy, regulations and safety in India (1,2) 23–30
Gulliamier, R.A., see Savona-Ventura, C. (4) 177–184
Hama, R., Biologicals in Japan (1,2) 59–68
Hotouras, A., see Looseley, A. (3) 131–137
Keogh, M., see Looseley, A. (3) 131–137
Kidpatrick, C., WHO save lives: Clean your hands (4) 235–236
Kinross, J., see Brodie, A. (4) 201–215
Kruszewski, S.P., see Paczynski, R.P. (3) 139–145
Lekkerkerker, F., Are there safety concerns for biosimilars? (1,2) 47–52
Löfgren, H., The global biopharma industry and the rise of Indian drug multinationals: Implications for Australian generics policy (1,2) 31–40
Looseley, A., A. Hotouras and M. Keogh, Patient safety and the aviation model: Medicine is still learning (3) 131–137
Lovaglio, P.G., Patient safety monitoring systems using regional administrative data (4) 217–227
Mantel-Teeuwisse, A.K., see Giezen, T.J. (1,2) 53–58
Moyinihan, R., see D’Arcy, E. (4) 185–191
Nyazov, R.R., see Ziganshina, L.E. (1,2) 75–88
Paczynski, R.P. and S.P. Kruszewski, A link between schizophrenia and diabetes?: Insights from the pre-antipsychotic era (3) 139–145
Ragnarsson, G., see Barnes, H.J. (1,2) 13–22
Rågo, L., Biosimilar medicines and safety: New challenges for pharmacovigilance (1,2) 5–11
Rastogi, S., Poor quality and improper use: A review of common reasons of possible adversity in Ayurvedic practice (3) 121–130
Rehan, H.S. and D. Chopra, Guide to reporting adverse drug reactions (4) 229–234
Rossignol, N., How the European Union reviews and approves ‘follow-on biologics’ or biosimilar products (1,2) 105–109
Savona-Ventura, C., G.G. Buttigieg and M. Gatt, Obstetric outcomes in immigrants of African nationality (3) 147–152
Schück, S. and N. Texier, Biosimilars: The French policy (1,2) 41–45
Straus, S.M.J.M., see Giezen, T.J. (1,2) 53–58
Sweileh, W.M., Pain medications in Palestinian households: Safety and wastage analysis (4) 193–200
Tada, H., see Nishimura, T. (3) 161–167
Texier, N., see Schück, S. (1,2) 41–45
Usdin, S., The Heparin Story (1,2) 93–103
Vincent, C., see Brodie, A. (4) 201–215
Wu, Z., see Chen, Y. (1,2) 69–74
Wu, Z.A., see Chen, Y. (1,2) 69–74
Yadav, A., see Gogtay, N.J. (1,2) 23–30
Zhang, C., see Chen, Y. (1,2) 69–74
Ziganshin, A.U., see Ziganshina, L.E. (1,2) 75–88
Ziganshina, L.E., R.R. Nyazov and A.U. Ziganshin, Biopharmaceuticals in the Russian Federation: A snapshot of policies for registration, reimbursement and use (1,2) 75–88